Last reviewed · How we verify
Beijing Kawin Technology Share-Holding Co., Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| PEG-IFN-SA /RBV | PEG-IFN-SA /RBV | phase 3 | Pegylated interferon-alpha with nucleoside analog | Interferon-alpha receptor; viral RNA polymerase | Virology/Infectious Disease | |
| Pegasys /RBV | Pegasys /RBV | phase 3 | Interferon alfa-2a (pegylated) + nucleoside analog combination | Interferon-alpha receptor; HCV RNA-dependent RNA polymerase | Virology/Hepatology |
Therapeutic area mix
- Virology/Hepatology · 1
- Virology/Infectious Disease · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Beijing Kawin Technology Share-Holding Co., Ltd.:
- Beijing Kawin Technology Share-Holding Co., Ltd. pipeline updates — RSS
- Beijing Kawin Technology Share-Holding Co., Ltd. pipeline updates — Atom
- Beijing Kawin Technology Share-Holding Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Beijing Kawin Technology Share-Holding Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/beijing-kawin-technology-share-holding-co-ltd. Accessed 2026-05-17.